DNA Methylation and Risk of Disease Recurrence Following Surgery in Patients With CD
Crohn’s disease
DISEASE, RECURRENCE
The composite clinical outcome used in the original TOPPIC trial consisting of an increase in Crohn’s disease activity index of more than 150 and an increase of 100 points from baseline measurement together with the institution of immunosuppressive treatment, or further surgery. Secondary outcomes of CD disease recurrence included the highest endoscopic scores (CDEIS, Rutgeerts) measured at 49 and 157 weeks following randomization. TOPPIC data alone were read into R and processed using the previously mentioned steps. DMP analysis (recurrence vs no recurrence) was performed as mentioned with the following covariates: age, sex, smoking status, treatment/placebo, and cell proportions. DVPs were assessed using the iEVORA package using the row_ievora() function in the matrixTests package with default parameter of a raw 